Author: Ravi Shankar

Two industry leaders formalize strategic relationship spanning the full tungsten value chain

Investment includes a 4.99% ownership stake and multi-year supply agreements across key production stages

Further advances the objectives of the United States Government’s $450 million committed investment announced September 14, 2026

PORTLAND, Maine, Sept. 23, 2026 (GLOBE NEWSWIRE) — The Elmet Group Co. (NASDAQ: ELMT) (“ELMT” or the “Company”), a U.S.-based provider of critical materials, precision-engineered components, and advanced high-energy systems, today announced a long-term strategic relationship with Vietnam-based Masan High-Tech Materials Corporation (UPCoM: MSR) (“MSR”) under which ELMT will acquire a 4.99% equity stake in MSR for $124.75 million. The acquisition formalizes a longstanding commercial relationship of more than 12 years, during which MSR has distinguished itself as a reliable supplier of high-quality tungsten materials and a valued strategic partner to ELMT.

Alongside the equity investment, the parties have entered into long-term commercial agreements under which MSR has agreed to supply ELMT with mined tungsten from its Nui Phao Mine and provide tungsten conversion services from its refining complex in Vietnam. The acquisition of an ownership stake and the commercial agreements establish a basis for ELMT and MSR to pursue increased refining throughput, new product development, and a broader international customer base.

“We value the opportunity to formalize our relationship with MSR, which furthers our progress toward a resilient tungsten supply chain,” said The Elmet Group CEO and Chairman Peter V. Anania. “During the 12 years we have worked alongside MSR, it has established itself as a proven tungsten producer with global significance. The Elmet Group is investing in the expansion of supply, refinement, and conversion of tungsten through this acquisition, building on the landmark investment we received from the United States Government to solidify our position as a vertically integrated, U.S.-based provider of critical materials.”

The technologies defining this century, including artificial intelligence, semiconductors and aerospace, cannot exist without tungsten,” said Chairman of Masan-High Tech Materials Danny Le. “The world can count on one hand the places that produce and refine it at scale. MSR is one of them. The Elmet Group has spent twelve years inside our supply chain. They know what we have built and what it would take to build again. That is what trust looks like when it converts into capital. Their investment speaks for itself. This is the beginning, and we will unlock MSR’s full value for shareholders in Vietnam and beyond.”

Robust and Complementary Capabilities

Together, the two companies connect the supply chain from ore to finished part: mining and concentration, chemical conversion, powder production, pressing and sintering, forming, and precision machining. MSR sits upstream, operating the Nui Phao Mine — one of the largest tungsten deposits in the world — alongside an integrated refining complex that converts concentrate into high-purity tungsten chemicals. ELMT sits downstream, transforming the materials processed by MSR into precision-engineered components for aerospace, defense, semiconductor, medical, industrial, and energy customers. Few relationships in the tungsten industry span such a broad range, and even fewer are reinforced by an equity relationship.

For ELMT, this formalized relationship is intended to secure long-term access to mined tungsten and conversion capacity at scale. For MSR, it is intended to secure a committed downstream industrial partner, additional third-party feedstock for its refinery, and a strategic shareholder with deep manufacturing expertise and access to diverse end markets.

These announcements follow the landmark investment ELMT received from the United States Government, announced on September 14, 2026. Each of these developments advance ELMT’s aim to become a robust provider of critical materials with capabilities and access throughout the full tungsten supply chain across key geographies around the world.

Completion of the equity investment is subject to customary closing conditions, including required regulatory and corporate approvals, and is expected to occur in the third quarter of 2026. The commercial agreements take effect upon completion. In connection with its new ownership position, ELMT will also receive one seat on MSR’s Board of Directors and support MSR’s planned uplisting to the Ho Chi Minh Stock Exchange, as well as its evaluation of an international listing.

About Masan High-Tech Materials
Masan High-Tech Materials is a leading global provider of advanced tungsten materials used across critical industries, including electronics, chemicals, automotive, aerospace, energy, and pharmaceuticals, serving customers worldwide. As the world’s largest producer of midstream and downstream tungsten products outside China, the Company operates the Nui Phao polymetallic mine and a state-of-the-art tungsten processing facility in Thai Nguyen Province, Vietnam. Masan High-Tech Materials is also a leading global producer of fluorspar and bismuth.

About The Elmet Group
The Elmet Group is a U.S.-based provider of critical materials, precision-engineered components, and advanced high-energy systems for the Aerospace, Defense and Government, Industrial, Medical, Semiconductor and Electronics, and Energy industries. The Company operates through three divisions: Critical Materials Components (CMC), Engineered Microwave Products (EMP), and Elmet Refining & Trading (ERT), leveraging materials science and precision engineering expertise to deliver high-performance solutions. The Elmet Group is dedicated to strengthening domestic manufacturing capabilities to support the U.S. and its Allies’ needs in both critical materials and advanced high-power microwave systems.

Media Contact
media@theelmetgroup.com

Investor Contact
Tom Colton and Greg Bradbury
Gateway Group, Inc.
ELMT@gateway-grp.com
949-574-3860

Forward-looking statements disclaimer
The information in this press release includes forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. These statements generally relate to future events or our future financial or operating performance and include statements regarding (i) the purchase price and closing timing of ELMT’s acquisition of a 4.99% stake in MSR, (ii) the ability of ELMT and MSR to successfully pursue increased refining throughput, new product development, and a broader international customer base; (iii) the ability of ELMT to become a vertically integrated, U.S.-based provider of critical materials with capabilities and access throughout the full Tungsten supply chain across key geographies around the world; (iv) the receipt of regulatory and corporate approvals to complete the investment; (v) Elmet’s receipt of a board seat on MSR’s Board of Directors and MSR’s planned uplisting to the Ho Chi Minh Stock Exchange; and (vi) ELMT’s future performance, expected outcomes and strategic initiatives.

When used in this press release, words such as “expect,” “project,” “estimate,” “believe,” “anticipate,” “intend,” “plan,” “seek,” “forecast,” “target,” “predict,” “may,” “should,” “would,” “could,” and “will,” the negative of these terms and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Forward-looking statements are based on management’s current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Elmet’s Registration Statement on Form S-1, as amended (File No. 333-294725) and subsequent filings Elmet makes with the Securities and Exchange Commission. Elmet undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

MCDONALD, Tenn., Sept. 23, 2026 (GLOBE NEWSWIRE) — Amaero Inc. (ASX:3DA) (“Amaero” or the “Company”), a leading U.S.-based producer of high-value refractory and titanium alloy spherical metal powders for additive manufacturing and advanced manufacturing, and a pioneer in Powder Metallurgy Hot Isostatic Pressing manufacturing of large near-net-shape components, today announced the postponement of its initial public offering due to adverse market conditions.

A Registration Statement on Form S-1 (File No. 333-298612) relating to the proposed offering of securities was filed with the U.S. Securities and Exchange Commission (the “SEC”) but has not yet been declared effective. Such securities may not be sold nor may offers to buy such securities be accepted prior to the time the registration statement is declared effective.   

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

For further information, please contact:

Amaero Inc.
Hank J. Holland
Chairman and CEO
hank.holland@amaeroinc.com

Media & Investor Enquiries in Australia
Jane Morgan
Director
jm@janemorganmanagement.com.au

Media & Investor Enquiries in United States
Shannon Devine
MZ Group
amaero@mzgroup.us

About Amaero

Amaero Inc. is a leading U.S.-based producer of high-value refractory and titanium alloy spherical metal powders for additive manufacturing (“AM”) and advanced manufacturing, and a pioneer in Powder Metallurgy Hot Isostatic Pressing manufacturing of large near-net-shape components. With manufacturing and corporate headquarters in Tennessee, we occupy a strategically critical position at the intersection of U.S. national security priorities, AM technology, and the domestic reshoring of imperative U.S. supply chains.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place on October 23-27, 2026, in Madrid, Spain.

Notably, results from two positive Phase III studies evaluating the savolitinib and osimertinib combination have been selected for oral presentations. Results from the global SAFFRON study will be featured in the Presidential Symposium session, while results from the SANOVO study in China will be presented in a Proffered Paper session, both highlighting important new clinical data. Having two Phase III studies featured as late-breaking abstracts underscores the potential of this all-oral, chemo-free combination to deliver meaningful advancements for patients with non-small cell lung cancer (“NSCLC”).

The SAFFRON Global Phase III Study has been selected for a Presidential Symposium oral presentation. The study evaluated the combination in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC with MET overexpression or amplification following disease progression on osimertinib. The trial reported positive high-level results on August 17, 2026, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (“PFS”) and overall survival (“OS”) compared to doublet platinum-based chemotherapy.

The SANOVO China Phase III Study has been selected for a Proffered Paper oral presentation. The study evaluated the combination in previously untreated patients with locally advanced or metastatic NSCLC harboring activating EGFR mutations and MET overexpression. The trial reported positive high-level results on August 31, 2026, demonstrating a statistically significant and clinically meaningful improvement in PFS and a clinically meaningful benefit in OS versus osimertinib monotherapy.

Details of the presentations are as follows:

Abstract title	Presenter / Lead author	Presentation details
SPONSORED STUDIES
Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results	Shun Lu (Shanghai, China)	LBA6 Presidential Symposium II Alicante Auditorium – Hall 6 Sunday, October 25, 2026 16:30 – 18:15 CEST
Savolitinib or Placebo Combined with Osimertinib in Treatment-Naïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results from the Phase 3 SANOVO Study	Yi-Long Wu (Guangzhou, China)	LBA69 Proffered paper 2: NSCLC, metastatic Alicante Auditorium – Hall 6 Monday, October 26, 2026 08:30 – 10:00 CEST
Updated results from a fruquintinib Expanded Access Program for patients with previously treated metastatic colorectal cancer	Stefan Kasper (Essen, Germany)	848P Poster Session: Colon cancer
Association between dose adjustment and treatment outcomes in patients with advanced renal cell carcinoma receiving fruquintinib plus sintilimab: A post-hoc analysis of the FRUSICA-2 trial	Yuanyuan Qu (Shanghai, China)	3655eP E-poster Session: Renal cancer
Efficacy of fruquintinib plus sintilimab in special populations with advanced renal cell carcinoma: A subgroup analysis of FRUSICA-2 study	Kaiwei Yang (Beijing, China)	3667eP E-poster Session: Renal cancer
Final phase 2 analysis of surufatinib plus camrelizumab, nab-paclitaxel and gemcitabine in first-line metastatic pancreatic cancer	Shukui Qin (Nanjing, China)	3156P Poster Session: Pancreatic cancer
INVESTIGATOR-INITIATED STUDIES
Fruquintinib plus capecitabine maintenance after first-line anti-EGFR antibody plus chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer: A phase Ib/II study	Lin Yang/ Letian Zhang (Beijing, China)	877eP E-poster Session: Colon cancer
Real-world effectiveness and safety of fruquintinib in patients with metastatic colorectal cancer in Spain: The FrESP study	Ana Fernandez Montes (Ourense, Spain)	880eP E-poster Session: Colon cancer
CONCEPT (COmbinatioN of CEtuximab Plus fruquintinib Treatment ± immunotherapy): A multicenter, randomized, open-label phase II trial in first-line pMMR RAS/BRAF wild-type unresectable metastatic colorectal cancer	Kefeng Ding (Hangzhou, China)	890eP E-poster Session: Colon cancer
A real-world study of low-dose fruquintinib combined with trifluridine/tipiracil hydrochloride (TAS-102) in the third-line and beyond treatment of metastatic colorectal cancer	Yuehong Cui/ Li Liang (Shanghai, China)	903eP E-poster Session: Colon cancer
Real-world outcomes with fruquintinib in heavily pretreated metastatic colorectal cancer: Impact of patient and disease characteristics	Maria Maddalena Laterza (Pozzuoli, Italy)	964eP E-poster Session: Colon cancer
A phase II, open-label, randomized study of doublet chemotherapy (FOLFOX or FOLFIRI) plus fruquintinib compared with doublet chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab in second line setting for a metastatic colorectal cancer: ULYSSE- FFCD2406 – PRODIGE115 (trials in progress)	Jean Marc Phelip (Saint-Étienne, France)	991eTiP E-poster Session: Colon cancer
Phase II study of fruquintinib plus utidelone in platinum-resistant recurrent ovarian cancer (FRUTD Trial)	Zheng Feng (Shanghai, China)	1283P Poster Session: Gynaecological cancers
Fruquintinib plus eribulin in patients with metastatic HR+, HER2–breast cancer after progression on endocrine therapy plus CDK4/6 inhibitor: Updated results from a phase II study	Yuan Yuan (Nanjing, China)	1896eP E-poster Session: HR+ breast cancer
Fruquintinib plus sintilimab and XELOX as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, open-label, multicenter phase II study	Hua Wang (Nanchang, China)	2980eP E-poster Session: Oesophagogastric cancer
Fruquintinib plus cadonilimab and S-1 in previously treated unresectable locally advanced or metastatic esophageal squamous cell carcinoma: preliminary efficacy and safety results from a phase Ib/II study	Huiyan Luo (Guangzhou, China)	2981eP E-poster Session: Oesophagogastric cancer
Nanoliposomal irinotecan (nal-IRI) combined with fruquintinib as second-line treatment for advanced gastric cancer: A single-arm, open-label, dose-escalation and expansion phase I/II trial	Jieer Ying/ Qi Xu (Hangzhou, China)	2986eP E-poster Session: Oesophagogastric cancer
FRUQUITAS trial: ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma	David Tougeron (Poitiers, France)	3079eTiP E-poster Session: Oesophagogastric cancer
CHOICE III: short-course preoperative radiotherapy followed by fruquintinib plus anti–PD-1 antibody (serplulimab) for neoadjuvant treatment of pMMR/MSS mid-to-low locally advanced rectal cancer: A single-arm, single-center, prospective phase II study	Wei Zhang (Shanghai, China)	3582eTiP E-poster Session: Rectal and anal cancer
First-line fruquintinib plus serplulimab for metastatic non-clear cell renal cell carcinoma: Updated results from the phase II FRONTIER study	Jiwei Huang (Shanghai, China)	3614P Poster Session: Renal cancer
Latest efficacy and safety analysis of surufatinib combined with EP regimen and serplulimab as first-line treatment for extrapulmonary neuroendocrine carcinoma	Tao Zhang/ Zhenyu Lin (Wuhan, China)	2394RO Rapid Oral Session: NETs and endocrine tumours Pamplona Auditorium – Hall 5 Friday, October 23, 2026 16:15 – 17:45 CEST
Surufatinib combined with toripalimab and nab-paclitaxel/ gemcitabine chemotherapy as first-line treatment for advanced pancreatobiliary-type ampullary carcinoma: A prospective phase II Clinical Trial	Juan Du (Nanjing, China)	507eP E-poster Session: Biliary tract cancer, incl. cholangiocarcinoma
Efficacy and safety of surufatinib in combination with CAPTEM in advanced G2/G3 Neuroendocrine Tumors: Results from a single-arm, phase II Trial	Wei Wang (Guangzhou, China)	2403P Poster Session: Neuroendocrine tumours
Surufatinib plus S-1/temozolomide as first-line therapy in MGMT-low advanced pancreatic neuroendocrine tumours (SUSTEM-p): An open-label, single-centre phase Ib/II trial	Yihebali Chi (Beijing, China)	2411P Poster Session: Neuroendocrine tumours
Updated results of a prospective, open-label study of surufatinib plus CAPTEM as conversion therapy for unresectable pancreatic neuroendocrine tumors	Ziyao Wang (Chengdu, China)	2412P  Poster Session: Neuroendocrine tumours
Matching-adjusted indirect comparison of surufatinib versus high-dose OCT-LAR in patients with advanced GEP-NETs who progressed on prior SSA Therapy	Jianming Xu (Beijing, China)	2415P Poster Session: Neuroendocrine tumours
Surufatinib combined with octreotide LAR for the treatment of G1/G2 GEP-NETs: A single-arm, prospective, open-label phase II study	Xiaofeng Sun (Nanjing, China)	2439eP E-poster Session: Neuroendocrine tumours
Six weeks of induction gemcitabine plus nab paclitaxel (AG) followed by sequential surufatinib plus AG or AG alone as first line therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC): A single center, two cohort, phase II study	Jin Xu/ Jialin Li (Shanghai, China)	3168P Poster Session: Pancreatic cancer
A phase Ib/II study of radiotherapy combined with surufatinib and sintilimab for localized high-risk limb and trunk soft tissue sarcomas: A prospective single-center trial	Yan Wang (Shanghai, China)	3739P Poster Session: Sarcoma
Surufatinib plus serplulimab, etoposide, and carboplatin as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC): Updated results from a single-arm, phase Ia/Ib trial	Haipeng Xu/ Longfeng Zhang (Fuzhou, China)	3831P Poster Session: Small cell lung cancer

About Fruquintinib
Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE^®. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA^®.

About Savolitinib
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS^®.

About Surufatinib
Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA^®. HUTCHMED currently retains all rights to surufatinib worldwide.

About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, surufatinib and savolitinib, the further clinical development for fruquintinib, surufatinib and savolitinib, its expectations as to whether any studies on fruquintinib, surufatinib and savolitinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, surufatinib and savolitinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, surufatinib and savolitinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as sintilimab and toripalimab as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

EssilorLuxottica and Meta further advance AI glasses category
with new products revealed at Meta Connect

The two companies introduce new line of audio AI glasses and next generation of
Ray-Ban Meta, the world’s leading AI glasses

Paris, France and Menlo Park, California (24 September 2026) – EssilorLuxottica and Meta Platforms, the partnership behind the fast-growing smart eyewear category, unveiled the next generation of AI glasses at Meta Connect. Expanding their groundbreaking portfolio of products, the companies announced a new line of audio glasses, a third generation of Ray-Ban Meta, as well as new models, features and geographies for existing products. By the end of this year, the companies will offer more than 100 different styles of AI glasses. And they announced Meta’s new personal AI agent, Muse, will be coming to AI glasses.

Ray-Ban Meta Audio: Given that audio is consistently Ray-Ban Meta’s most popular feature, particularly because the glasses deliver high-quality sound without having to close off the world around you, the companies have introduced Ray-Ban Meta Audio, a camera-free line of AI glasses, their lightest and slimmest yet, weighing as low as 43 grams, offering maximum comfort with professional-adjustable temple tips, adjustable or swappable nose pads and overextension hinges ensuring a perfect fit for all-day wear. Ray-Ban Meta Audio will launch in two new styles: Clubmaster and Burbank, both compatible with a wide range of optical prescriptions. 

Ray-Ban Meta Gen 3: Also unveiled at Meta Connect was the next generation of the world’s leading AI glasses: Ray-Ban Meta Gen 3 comes in a slimmer, more comfortable design with longer battery life and a customizable action button for instant access to Meta AI. The Gen 3 collection, which comes in 27 color and lens combinations, will now include one of the most legendary silhouettes, the Aviator, which is celebrating its 90^th anniversary, making it a milestone moment for the brand. The collection will also include Zena, a bold new style with a distinctive and modern cat eye look, and the iconic Wayfarer in both standard and large sizes.

Opening the category to new audiences: Meta Glasses with EssilorLuxottica are also expanding with two new styles – Capri and Nova – to offer a wider consumer choice and introducing also two new models designed with the international icon, LISA. These round out the most expansive and accessible portfolio of AI glasses.

A richer AI glasses experience: Muse, a personal AI agent, is coming to all the companies’ AI glasses (available in US only), handling tasks hands-free so wearers can stay present. Capture also improves with Dynamic Photo and Landscape Crop Mode, alongside support for Dolby Atmos. Finally, Hearing Enhancement (available in US only), an FDA-cleared software feature for adults with perceived mild to moderate hearing loss, arrives via one-time payment or subscription later this year. Powering the next generation of AI capabilities with consumer privacy in mind, Meta will bring “private processing” to AI glasses later this year. The portfolio of AI glasses from EssilorLuxottica and Meta will welcome new features ranging from guided workouts and nutrition, expanding navigation with cycling and public transit directions.

Global retail expansion: EssilorLuxottica is bringing the already loved portfolio of AI glasses to more consumers, expanding in the coming months in these new markets: Poland, Portugal, Israel, South Africa, Indonesia, Thailand, Hong Kong, New Zealand, Malaysia and the Philippines. Additionally, Meta Ray-Ban Display are now available to purchase online and are expanding into five new markets. The glasses go on sale today in the UK and Canada. Pre-orders will progressively start from today in France, Italy and Germany, initially through select retail locations in Vancouver, Toronto, London, Paris, Milan, Rome, Frankfurt, Hamburg and Munich.

“From launching the original Ray-Ban Stories five years ago to building a powerful assortment of AI glasses with strong consumer choice across brands, price points and tech features, we’re proud of our pioneering role in the category. As we expand with new innovations that have long been in the works like Ray-Ban Meta Audio, and develop new use cases for glasses, our ability to anticipate and deliver on consumer needs and desires will grow even stronger,” commented Francesco Milleri, Chairman and CEO, EssilorLuxottica.

“AI glasses need to match people’s individual sense of style while looking and feeling great on every kind of face. Meta and EssilorLuxottica are working to make sure every person can find the right pair for them, and the products we announced today bring new options for everyone,” said Mark Zuckerberg, CEO, Meta.

Attachment

• DOWNLOAD THE PRESS RELEASE

SALT LAKE CITY, Sept. 23, 2026 (GLOBE NEWSWIRE) — Medallion Bank (Nasdaq: MBNKO), an FDIC-insured bank providing consumer loans for the purchase of recreational vehicles, boats, and home improvements, along with loan origination services to fintech strategic partners, announced today that it has priced a public offering of 2,200,000 additional shares of its Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series G, par value $1.00 per share, with a liquidation amount of $25 per share (the “Series G Preferred Stock”) and an aggregate liquidation amount of $55,000,000. The offering is a reopening of Medallion Bank’s original issuance of its Series G Preferred Stock, which occurred on May 22, 2025.

Dividends will accrue on the liquidation amount of $25 per share of the Series G Preferred Stock at a fixed rate per annum equal to (i) 9.00% from the original issue date of the Series G Preferred Stock to, but excluding, July 1, 2030, and (ii) from and including July 1, 2030, at a rate equal to the five-year U.S. Treasury rate plus 4.94% per annum. Dividends will be payable in arrears on January 1, April 1, July 1 and October 1 of each year. In each case, dividends will be paid only when, as and if declared by the board of directors of Medallion Bank (or a duly authorized committee of the board) and to the extent Medallion Bank has legally available funds to pay dividends. Because the original issue date of the shares being offered will occur after the record date for the next Series G Preferred Stock dividend payment date on October 1, 2026, dividends on the offered shares, if declared, will accrue from October 1, 2026, and will be payable commencing on January 1, 2027.

Medallion Bank’s Series G Preferred Stock is traded on the Nasdaq Capital Market under the ticker symbol “MBNKO.” The underwriters have also been granted a 30-day option to purchase up to an additional 330,000 shares of the Series G Preferred Stock solely to cover over-allotments, if any. Medallion Bank will remain a wholly owned subsidiary of Medallion Financial upon completion of the offering.

Medallion Bank intends to use the net proceeds from this offering for general corporate purposes, which may include, among other things, redeeming some or all of its outstanding Senior Series E Non-Cumulative Perpetual Preferred Stock (the “Series E Preferred Stock”), subject to the prior approval of the Federal Deposit Insurance Corporation. The offering is expected to close on September 30, 2026, subject to customary closing conditions.

Piper Sandler & Co., Lucid Capital Markets, LLC, Muriel Siebert & Co., LLC, A.G.P. / Alliance Global Partners, and Ladenburg Thalmann & Co. Inc. are acting as joint book-running managers. William Blair & Company, L.L.C., InspereX LLC, B. Riley Securities, Inc., and Clear Street LLC are acting as lead managers.

The offering of the Medallion Bank’s Series G Preferred Stock is exempt from the registration requirements of the Securities Act of 1933 pursuant to Section 3(a)(2) of that Act and will be made only by means of an offering circular. This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. The securities are neither insured nor approved by the Federal Deposit Insurance Corporation or any other Federal or state regulatory body.

The preliminary offering circular relating to the offering is available at medallionbankoffering.com. In addition, copies of the preliminary offering circular may also be obtained from: Piper Sandler & Co.; Attn: Debt Capital Markets, 1251 Avenue of the Americas, 6th Floor, New York, 10020, or by email at fsg-dcm@psc.com.

About Medallion Bank

Medallion Bank specializes in providing consumer loans for the purchase of recreational vehicles, boats, and home improvements, along with loan origination services to fintech strategic partners. The Bank works directly with thousands of dealers, contractors and financial service providers serving their customers throughout the United States. Medallion Bank is a Utah-chartered, FDIC-insured industrial bank headquartered in Salt Lake City and is a wholly owned subsidiary of Medallion Financial Corp.
For more information, visit www.medallionbank.com

This press release contains “forward-looking statements”, which reflect Medallion Bank’s current views with respect to future events and which address matters that are, by their nature, inherently uncertain and beyond Medallion Bank’s control. These statements are often, but not always, made through the use of words or phrases such as “expect” and “intend” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These statements relate to the offering of shares of the Series G Preferred Stock, the anticipated use of the net proceeds by Medallion Bank and the grant to the underwriters of an option to purchase additional shares of the Series G Preferred Stock. No assurance can be given that the transaction discussed above will be completed on the terms described, or at all, or that Medallion Bank will decide to redeem its Series E Preferred Stock or, if it does, the amount to be redeemed and the timing of redemption and required regulatory approval. Completion of the offering on the terms described, including the grant of the option to the underwriters, and the application of net proceeds, are subject to numerous conditions, many of which are beyond the control of Medallion Bank. Medallion Bank undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. For a description of certain risks to which Medallion Bank is or may be subject, please refer to the factors discussed under the headings “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors,” in Medallion Bank’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026.

This press release does not constitute a notice of redemption with respect to the Series E Preferred Stock.

Company Contact

Investor Relations

212-328-2176

investorrelations@medallion.com

LOS ANGELES, Sept. 23, 2026 (GLOBE NEWSWIRE) — Hanmi Financial Corporation (NASDAQ: HAFC, or “Hanmi”), and its wholly-owned subsidiary, Hanmi Bank (the “Bank”), today announced its inclusion in the Piper Sandler Sm-All Stars Class of 2026, recognizing the Bank’s strong financial performance and operating fundamentals. Only 25 institutions nationwide earned recognition in the 2026 class. This is the second time that Hanmi Bank has been recognized in the Piper Sandler Sm-All Stars.

Piper Sandler awards this designation annually to a select group of banks and thrifts with market capitalizations below $2.5 billion that exceed industry median performance in key measures of earnings growth, loan growth, deposit growth, and return on average equity, while also meeting stringent asset quality and capital standards.

“We are honored to be recognized by Piper Sandler as a member of its 2026 Sm-All Stars,” said Bonnie Lee, President and Chief Executive Officer. “We believe this recognition underscores our strong financial performance, which reflects the success of our customer relationship banking model, our disciplined approach to risk management, and the dedication of our employees. As we continue to execute our strategic priorities, we remain focused on delivering consistent performance and long-term value for our shareholders.”

About Hanmi Financial Corporation
Headquartered in Los Angeles, California, Hanmi Financial Corporation owns Hanmi Bank, which serves multi-ethnic communities through its network of 32 full-service branches, five loan production offices and three loan centers in California, Texas, Illinois, Virginia, New Jersey, New York, Colorado, Washington and Georgia. Hanmi Bank specializes in real estate, commercial, SBA and trade finance lending to small and middle market businesses. Additional information is available at www.hanmi.com.

Media Contact:
Kelly Hull
Financial Profiles, Inc.
khull@finprofiles.com
310-622-8252

Investor Contacts:
Romolo (Ron) Santarosa
Senior Executive Vice President & Chief Financial Officer
213-427-5636

Lisa Fortuna
Investor Relations
Financial Profiles, Inc.
lfortuna@finprofiles.com
310-622-8251

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) (the “Company” or “GoldHaven”) is pleased to announce that it has closed a further tranche of its previously announced non-brokered flow-through financing (the “Flow-Through Offering”) through the issuance of 4,206,906 flow-through common shares (the “FT Shares”) at a price of $0.265 per FT Share for aggregate proceeds of $1,114,830.

With the completion of this tranche, GoldHaven has raised aggregate gross proceeds of approximately $3.0 million under the Flow-Through Offering.

The additional capital is expected to provide GoldHaven with increased financial flexibility to advance exploration at its Magno Project and build upon the Company’s ongoing 2026 exploration program.

Rob Birmingham, CEO of GoldHaven, commented: “We are very pleased with the strong support for this financing and the additional demand that allowed us to close approximately $3.0 million. This capital strengthens our ability to advance the exploration program at Magno and build on the momentum we have established on the ground. We appreciate the continued support from both existing and new investors as we move through this important phase of exploration.”

In connection with the closing, the Company paid cash finder’s fees totaling $27,825 and issued 105,000 non-transferable finder warrants (each, a “Finder Warrant”) to certain eligible arm’s-length finders who introduced subscribers to the Offering. Each Finder Warrant entitles the holder to purchase one common share (a “Finder Share”) at a price of $0.35 per Finder Share for a period of 24 months from the date of issuance. All securities issued pursuant to the Offering are subject to a statutory hold period expiring four months plus one day from closing, in accordance with applicable securities laws and Canadian Securities Exchange requirements.

USE OF PROCEEDS

The gross proceeds from the Offering will be used to incur eligible Canadian exploration expenses that will qualify as “Critical Mineral Mining Expenditures” as defined under the Income Tax Act (Canada). The expenditures will be renounced to subscribers effective December 31, 2026.

Funds from the Offering are expected to support ongoing exploration and advancement of the Company’s Magno Project.

On Behalf of the Board of Directors

Rob Birmingham, Chief Executive Officer

For further information, please contact:
Rob Birmingham, CEO
www.GoldHavenresources.com
info@goldhavenresources.com
Office Direct: (604) 629-8254

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE- Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

This news release contains forward-looking statements and forward-looking information (collectively, “forward looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein including, without limitation, those listed below under the heading “Forward-Looking Statements in This News Release” are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: “believes”, “will”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “may”, “should”, “potential”, “scheduled”, or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that there will be investor interest in future financings, market fundamentals will result in sustained precious metals demand and prices, the receipt of any necessary permits, licenses and regulatory approvals in connection with the future exploration and development of any future projects in a timely manner, the availability of financing on suitable terms for exploration and development of future projects and the Company’s ability to comply with environmental, health and safety laws.

The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors, including, operating and technical difficulties in connection with mineral exploration and development activities, actual results of exploration activities, the estimation or realization of mineral reserves and mineral resources, the inability of the Company to obtain the necessary financing required to conduct its business and affairs, as currently contemplated, the inability of the Company to enter into definitive agreements in respect of possible Letters of Intent, the timing and amount of estimated future production, the costs of production, capital expenditures, the costs and timing of the development of new deposits, requirements for additional capital, future prices of precious metals, changes in general economic conditions, changes in the financial markets and in the demand and market price for commodities, lack of investor interest in future financings, accidents, labour disputes and other risks of the mining industry, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, changes in laws, regulations and policies affecting mining operations, title disputes, the inability of the Company to obtain any necessary permits, consents, approvals or authorizations, including by the Exchange, the timing and possible outcome of any pending litigation, environmental issues and liabilities, and risks related to joint venture operations, and other risks and uncertainties disclosed in the Company’s latest interim Management’s Discussion and Analysis and filed with certain securities commissions in Canada. All of the Company’s Canadian public disclosure filings may be accessed via www.sedarplus.ca and readers are urged to review these materials.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this news release or incorporated by reference herein, except as otherwise required by law.

Forward-Looking Statements in This News Release

The following statements in this news release constitute forward-looking information:

• The expectation that the additional capital will provide GoldHaven with increased financial flexibility to advance exploration at its Magno Project and build upon the Company’s ongoing 2026 exploration program
• GoldHaven’s plan to further strengthen its exploration program at Magno while maintaining the momentum established on the ground
• The expenditures from the Offering being renounced to subscribers effective December 31, 2026

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final September 2026 cash distributions for the iShares Premium Money Market ETF. Unitholders of record on September 24, 2026 will receive cash distributions payable on September 29, 2026.

Details regarding the final “per unit” distribution amounts are as follows:

Fund Name	Fund Ticker	Cash Distribution Per Unit
iShares Premium Money Market ETF	CMR	$0.093

Further information on the iShares ETFs can be found at http://www.blackrock.com/ca.

About BlackRock
BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate.

About iShares ETFs
iShares unlocks opportunity across markets to meet the evolving needs of investors. With more than twenty years of experience, a global line-up of more than 1,700 exchange traded funds (ETFs) and approximately $6.2 trillion in assets under management as of June 30, 2026, iShares continues to drive progress for the financial industry. iShares funds are powered by the expert portfolio and risk management of BlackRock.   

iShares^® ETFs are managed by BlackRock Canada.

Commissions, trailing commissions, management fees and expenses all may be associated with investing in iShares ETFs. Please read the relevant prospectus before investing. The funds are not guaranteed, their values change frequently and past performance may not be repeated. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional.

Contact for Media:
Sydney Punchard
Email: Sydney.Punchard@blackrock.com

Vectus CEO Erik Prince confirms intent to purchase at least 40 Swarmer-built air defense systems in year one and 80 or more in year two following the start of production in Poland

AUSTIN, Texas, Sept. 23, 2026 (GLOBE NEWSWIRE) — Swarmer, Inc (“Swarmer”) (NASDAQ: SWMR), a drone autonomy platform company that has supported more than 100,000 real-world combat missions in Ukraine since April 2024, today announced it has signed a nonbinding memorandum of understanding with Vectus Air Defense Systems, a company in which Swarmer holds a 20% interest, to manufacture, sell and deploy end-to-end air defense systems in eligible markets, subject to applicable export-control, sanctions, procurement, and other governmental requirements.

Swarmer intends to establish an air defense system manufacturing facility in Poland. Under the memorandum, Vectus has confirmed its intent to purchase and deploy at least 40 Swarmer-built systems in year one and 80 or more in year two following the start of production.

“We intend to manufacture an end-to-end solution that includes radars, cameras, fire control and effectors to target a variety of threats, including newer jet-powered Shahed-type attack drones,” said Alex Fink, Swarmer U.S. CEO and president. “The systems use combat-proven Gatling-type rotary cannons, capable of firing 20mm rounds at a rate of up to 6,000 rounds per minute, as the last line of defense.”

Fink estimates each system will retail at approximately $5 million to $6 million. Gun-based kinetic effectors are intended to significantly reduce the cost per kill compared with multimillion-dollar precision-guided missiles. Historically, drones are much cheaper than the missiles used to intercept them, whereas 20mm ammunition is relatively inexpensive and widely available.

“In my experience, high-powered rotary cannons produce a wall of lead that few aerial threats can survive,” said Erik Prince, who acts as both Vectus’ CEO and Swarmer’s board chairman. “I believe these systems will be in high demand because they are portable, affordable and designed to destroy targets on impact. High-speed enemy drones may outfly an interceptor, but they can’t outfly thousands of 20mm rounds.”

Final quantities, pricing, financing, specifications, and delivery schedules remain subject to definitive agreements.

About Swarmer

Swarmer™ (Nasdaq: SWMR) is a defense technology company that specializes in vendor-agnostic software which allows one operator to intuitively control hundreds of autonomous platforms in real time. Swarmer’s primary mission areas include autonomous swarm coordination, integration of multi-domain unmanned systems and AI-powered autonomy software for distributed operations. Swarmer’s technology has been rigorously validated in real-world kinetic environments and was first deployed in combat operations in Ukraine in April 2024. Since then, it has completed more than 100,000 combat missions, generating terabytes of proprietary data that informs its machine-learning models and enables the replication of advanced pilot performance at scale. Swarmer’s routine use in combat missions generates continuous streams of telemetry, sensor data and operational feedback which are then used to refine performance, increase resilience and accelerate learning. Swarmer has headquarters in Austin, Texas, and maintains operations and teams in Ukraine, Poland and Estonia. For more information, visit www.swarmer.com.

About Vectus Air Defense Systems

Vectus Air Defense Systems provides Air Defense as a Service for sovereign governments and critical infrastructure operators. The company designs, integrates and continuously operates layered air-defense systems under multi-year service agreements, while monitoring evolving threats and upgrading deployed systems as technologies and tactics change. Its mission is to help ensure that critical infrastructure remains operational when disruption is not an option. For more information, visit: https://www.vectusairdefense.com.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements that are not historical facts, including statements concerning the negotiation and execution of definitive agreements between Swarmer and Vectus; the proposed establishment, timing, financing and operation of manufacturing operations in Poland; the anticipated development, manufacturing, pricing, commercial availability, sales, purchase, deployment, delivery, capabilities and performance of the air defense systems; Vectus’ intended purchases including anticipated quantities and timing; potential customer demand, cost savings and market opportunity; Swarmer’s product roadmap, commercialization plans, customer adoption, growth strategy and defense technology strategy; and any other statements using words such as “anticipate,” “believe,” “can,” “could,” “designed,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “seek,” “should,” “will,” “would” or similar expressions.

These forward-looking statements are based on current expectations, estimates, assumptions and beliefs and are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties include, among others: the risk that the nonbinding memorandum of understanding may be terminated or may not result in definitive agreements or binding purchase orders; the risk that Vectus may purchase fewer systems than currently contemplated or none at all; the risk that required financing, permits, regulatory approvals or governmental authorizations may not be obtained or may be subject to conditions; the risk that the proposed manufacturing operations in Poland may be delayed, reduced in scope or not established; the risk that final pricing, quantities, configurations, delivery schedules and other commercial terms may differ from current expectations; the risk that product development, testing, validation, commercial availability, production or deliveries may be delayed or unsuccessful; risks associated with sourcing and integrating radars, cameras, fire-control systems, effectors, ammunition and other third-party components; reliance on partners, suppliers, customers and government stakeholders; technical, operational, cybersecurity, safety and field-performance risks; the risks related to government, defense and international procurement processes; risks related to operating in or supporting customers in active conflict zones, including Ukraine; geopolitical, sanctions, export-control, defense-trade-control and other regulatory risks; competition in the defense technology sector; and the risk that the transactions and relationships described in this press release may not produce the anticipated operational, commercial, technical or strategic benefits.

Forward-looking statements speak only as of the date of this press release. Swarmer undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Additional risks and uncertainties are described in Swarmer’s filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in Swarmer’s registration statement and other filings filed with or furnished to the SEC.

Investor Contact (Swarmer): swmr@gateway-grp.com 

Media Contact (Swarmer): media@swarmer.tech 

Dr. Jennifer Billingsley Appointed President

PHOENIX, Sept. 23, 2026 (GLOBE NEWSWIRE) — Aspen Group, Inc. (“AGI”) (OTCQB: ASPU), an education technology holding company and the parent company of Aspen University (AU) and United States University (USU), announced today that Dr. Scott Burrus has resigned as President of USU and AU (the “Universities”), effective September 23, 2026. Dr. Jennifer Billingsley, DNP, FNP-BC, CNE, currently Provost and Chief Academic Officer of the Universities, has been appointed President, effective immediately.

Dr. Billingsley brings more than 20 years of experience in academic leadership, higher education and clinical practice to the role. As a member of the Aspen Group leadership team for over 8 years, she is currently serving in the role of Provost and Chief Academic Officer where she oversees USU’s and AU’s academic programs, student services, accreditation and faculty development. Dr. Billingsley previously served as Dean and Professor of USU’s College of Nursing and Health Sciences, where she helped launch the University’s first doctoral program, supported the Commission on Collegiate Nursing Education (“CCNE”) accreditation and led initiatives focused on student success and faculty development.

“Jennifer is an accomplished academic leader who has played an important role in the development of our institutions,” said Matt LaVay, Chief Executive Officer of Aspen Group. “Her deep knowledge of their academic programs and students, together with her experience in accreditation and academic leadership, makes her well suited to lead them through their next phase, including the pending merger of AU into USU. We look forward to working with Jennifer as we continue to advance our academic programs and support student success.”

LaVay continued, “On behalf of USU and AU, I would also like to thank Scott for his leadership and contributions to the Universities. During his tenure, Scott played an important role in the academic and institutional development of both institutions. We appreciate his service and wish him all the best in his future endeavors.”

Prior to joining USU’s senior leadership team, Dr. Billingsley served as Dean and Professor of the College of Nursing and Health Sciences. Earlier in her career, she served at Grand Canyon University, including as Chair of the Doctor of Nursing Practice program. She holds a Doctor of Nursing Practice and Master of Nursing in Family Nurse Practitioner from Grand Canyon University and a Bachelor of Science in Nursing from Arizona State University.

“I am honored to have the opportunity to serve as President of both USU and AU,” said Dr. Billingsley. “I have had the privilege of working alongside our faculty, staff and students and have seen firsthand their commitment to academic excellence and student success. I look forward to building on that foundation as we continue to advance the Universities’ mission and provide accessible, high-quality educational opportunities for our students.”

About Aspen Group, Inc.

Aspen Group, Inc. is an education technology holding company that leverages its infrastructure and expertise to allow its two universities, United States University and Aspen University, to deliver on the vision of making college affordable again. For more information, visit www.aspu.com.

Contact Information:

Hayden IR
Kimberly Rogers
(385) 831-7337
Kim@HaydenIR.com